170 related articles for article (PubMed ID: 38395442)
1. Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control study.
Rask G; Wadsten C; Acs B; Hartman J; Fredriksson I; Garmo H; Wärnberg F; Sund M
Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38395442
[TBL] [Abstract][Full Text] [Related]
2. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
[TBL] [Abstract][Full Text] [Related]
3. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
4. Risk of death from breast cancer after treatment for ductal carcinoma in situ.
Wadsten C; Garmo H; Fredriksson I; Sund M; Wärnberg F
Br J Surg; 2017 Oct; 104(11):1506-1513. PubMed ID: 28832961
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
Almekinders MM; Bismeijer T; Kumar T; Yang F; Thijssen B; van der Linden R; van Rooijen C; Vonk S; Sun B; Parra Cuentas ER; Wistuba II; Krishnamurthy S; Visser LL; Seignette IM; Hofland I; Sanders J; Broeks A; Love JK; Menegaz B; Wessels L; Thompson AM; de Visser KE; Hooijberg E; Lips E; Futreal A; Wesseling J;
Br J Cancer; 2022 Oct; 127(7):1201-1213. PubMed ID: 35768550
[TBL] [Abstract][Full Text] [Related]
6. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
7. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
8. Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer.
Giannakeas V; Sopik V; Narod SA
JAMA Netw Open; 2020 Sep; 3(9):e2017124. PubMed ID: 32936299
[TBL] [Abstract][Full Text] [Related]
9. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
10. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
Moriya T; Silverberg SG
Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.
Ruszczyk M; Zirpoli G; Kumar S; Bandera EV; Bovbjerg DH; Jandorf L; Khoury T; Hwang H; Ciupak G; Pawlish K; Schedin P; Masso-Welch P; Ambrosone CB; Hong CC
Cancer Causes Control; 2016 Feb; 27(2):183-98. PubMed ID: 26621543
[TBL] [Abstract][Full Text] [Related]
12. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
[No Abstract] [Full Text] [Related]
14. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
[TBL] [Abstract][Full Text] [Related]
15. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics.
Tsang WY; Chan JK
Am J Surg Pathol; 1996 Aug; 20(8):921-43. PubMed ID: 8712293
[TBL] [Abstract][Full Text] [Related]
16. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
17. Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.
Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Roxanis I; Rakha EA
Mod Pathol; 2019 Oct; 32(10):1473-1485. PubMed ID: 31175326
[TBL] [Abstract][Full Text] [Related]
18. Patterns of aggressiveness: risk of progression to invasive breast cancer by mammographic features of calcifications in screen-detected ductal carcinoma in situ.
Lilleborge M; Falk RS; Hovda T; Holmen MM; Ursin G; Hofvind S
Acta Radiol; 2022 May; 63(5):586-595. PubMed ID: 33887963
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA; Iqbal J; Giannakeas V; Sopik V; Sun P
JAMA Oncol; 2015 Oct; 1(7):888-96. PubMed ID: 26291673
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
